PMID- 25006443
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140709
LR  - 20211021
IS  - 2045-8932 (Print)
IS  - 2045-8940 (Electronic)
IS  - 2045-8932 (Linking)
VI  - 4
IP  - 2
DP  - 2014 Jun
TI  - Use of pulmonary arterial hypertension-specific therapy in overweight or obese 
      patients with obstructive sleep apnea and pulmonary hypertension.
PG  - 244-9
LID - 10.1086/675987 [doi]
AB  - Pulmonary hypertension (PH) in overweight or obese patients with obstructive 
      sleep apnea (OSA) may be multifactorial. The effect of pulmonary artery 
      hypertension (PAH)-specific drugs on PH and exercise capacity in such patients is 
      unknown. We performed a retrospective review of overweight or obese patients with 
      OSA and PH who were treated with PAH-specific therapy in our PH clinic. We 
      identified 9 female and 2 male patients. The mean age +/- SD was 54.9 +/- 9.3 years. 
      The mean pulmonary artery pressure at the time of diagnosis of PH was 39.8 +/- 16.1 
      mmHg. The right atrial pressure was 11.1 +/- 4.5 mmHg, the pulmonary artery wedge 
      pressure was 14.1 +/- 2.9 mmHg, the cardiac index was 2.6 +/- 0.5 L/min/m(2), and the 
      pulmonary vascular resistance index was 10.6 +/- 7.1 Wood units/m(2). The 
      indications for use of PAH-specific therapy were dyspnea in association with 
      right heart failure (n = 4), persistent PH despite compliance with nocturnal 
      positive airway pressure (PAP) therapy (n = 4), or inability to tolerate PAP 
      therapy (n = 3). PH was treated with an endothelin receptor antagonist (n = 8) or 
      a phosphodiesterase-5 inhibitor (n = 3). The 6-minute walk distance (6MWD) 
      improved significantly, from 234 +/- 49.7 to 258 +/- 54.6 m (24 m [95% confidence 
      interval (CI): 6.5-341.5 m]; P = 0.014) over a period of 4.4 +/- 1.8 months (n = 8) 
      and from 241.7 +/- 48.5 to 289.9 +/- 91 m (48 m [95% CI: 5.5-90.8 m]; P = 0.033) in 
      those with a longer follow-up period of 12.1 +/- 6.4 months (n = 7). The systolic 
      pulmonary artery pressure dropped significantly, from 64 +/- 25.2 to 42 +/- 10.4 mmHg 
      (22 mmHg [95% CI: 4-40 mmHg]; P = 0.024) over a period of 6.1 +/- 4.1 months (n = 
      7). In conclusion, PAH-specific therapy resulted in significant improvement in 
      both PH and 6MWD.
FAU - Shujaat, Adil
AU  - Shujaat A
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 
      Jacksonville, Florida, USA.
FAU - Bellardini, Jason
AU  - Bellardini J
AD  - Department of Medicine, University of Florida, Jacksonville, Florida, USA.
FAU - Girdhar, Ankur
AU  - Girdhar A
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 
      Jacksonville, Florida, USA.
FAU - Bajwa, Abubakr A
AU  - Bajwa AA
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 
      Jacksonville, Florida, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pulm Circ
JT  - Pulmonary circulation
JID - 101557243
PMC - PMC4070789
OTO - NOTNLM
OT  - obstructive sleep apnea
OT  - pulmonary hypertension
OT  - therapy
EDAT- 2014/07/10 06:00
MHDA- 2014/07/10 06:01
PMCR- 2014/06/01
CRDT- 2014/07/10 06:00
PHST- 2013/04/25 00:00 [received]
PHST- 2014/01/07 00:00 [accepted]
PHST- 2014/07/10 06:00 [entrez]
PHST- 2014/07/10 06:00 [pubmed]
PHST- 2014/07/10 06:01 [medline]
PHST- 2014/06/01 00:00 [pmc-release]
AID - PC2013108 [pii]
AID - 10.1086/675987 [doi]
PST - ppublish
SO  - Pulm Circ. 2014 Jun;4(2):244-9. doi: 10.1086/675987.